In 1984 the FDA passed the Orphan Drug Act1 in an effort to push the industry to pursue the treatment of rare diseases that afflict less than 200,000 patients a year in the U.S. Under the original Orphan Drug Act, companies were eligible for several extra years of marketing exclusivity, without generic competition, if they were able…